Designing for an Outcome
A microdosing stack works best when it is designed backward from a goal. This page covers how compound selection, delivery format, and timing are matched to specific neurological targets: the public framework behind Evōke's precision approach.
From Mechanism to Outcome
Most microdosing discourse starts with a compound and works forward to claimed effects. The precision approach works differently: it starts with a neurological target, identifies the mechanisms relevant to that target, and selects compounds and delivery formats accordingly. This is the decision framework Evōke applies to formulation.
The distinction matters practically. A formulation designed for cognitive performance draws on DMN suppression, neural entropy, and BDNF upregulation, and the compounds and adjuncts selected are those with the strongest mechanistic relevance to those pathways. A formulation designed for emotional regulation draws on serotonergic modulation and DMN suppression, with different adjunct priorities. A consolidation-focused approach adds the Amanita layer at the appropriate timing point.
"The question is not 'what does microdosing do?' It is 'what specific neurological mechanisms are relevant to this outcome, and what formulation best addresses them?'"
Building a Microdosing Stack: Matching Compounds to Targets
The Science of When
Timing is not incidental to a precision protocol. It is part of the formulation. Different compounds have different windows of peak effect, and the sequencing of those windows determines what happens at the neurological level.
The opening phase
Psilocybin's acute effects, DMN suppression, increased neural entropy, are most pronounced in the hours following administration and begin subsiding within a day. BDNF upregulation and structural synaptic changes persist longer, days to weeks. The opening phase creates the conditions; what follows determines what forms within them.
The consolidation window
Memory consolidation research shows that the period following new learning, particularly sleep, is when new synaptic configurations are stabilised. Sleep is also a state of heightened GABAergic inhibition, though GABA's specific contribution to consolidation is still being worked out. The consolidation hypothesis places Amanita muscaria in this window: supporting the stabilisation of what the plasticity window opened. The precise optimal timing is not yet established in controlled research.
The maintenance phase
Between dosing intervals, Lion's Mane, which stimulates NGF in laboratory and animal studies through pathways independent of 5-HT2A, is used to sustain neurogenesis support without an additional psilocybin dose. Human evidence is still limited to small trials. This is the rationale for daily Lion's Mane as a component of the broader protocol: bridging the intervals between opening doses.
The mechanism-to-outcome framework is public. The specific protocol, dose ranges, timing, formulation selection for individual goals, integration guidance, is documented in the Evōke member resource library. This is the line between science communication and therapeutic guidance, and it is where membership begins.
Evidence Landscape
Well established
Mechanism-to-compound mapping (all individual mechanisms documented in cluster pages) · Sleep-dependent memory consolidation · Stamets stack conceptual basis
Emerging
Lion's Mane NGF stimulation (strong in lab and animal studies, early in humans) · Stamets stack observational data · Protocol optimisation research · Timing effects on outcome · Multi-compound interaction studies · Fadiman protocol clinical evaluation
Not yet directly studied
Evōke entourage stack in controlled conditions · Optimal opening-consolidation timing · Individual variation in protocol response · Full outcome characterisation at sub-perceptual doses
References
- Fadiman J. (2011). The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys. Park Street Press.
- Rootman JM, et al. (2022). Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. Scientific Reports. 12:11091.
- Stickgold R. (2005). Sleep-dependent memory consolidation. Nature. 437:1272-1278.
- Tononi G, Cirelli C. (2014). Sleep and the price of plasticity: from synaptic and cellular homeostasis to memory consolidation and integration. Neuron. 81(1):12-34.
- Mori K, et al. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research. 23(3):367-372.
- Ly C, et al. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports. 23(11):3170-3182.
- Szigeti B, et al. (2021). Self-blinding citizen science to explore psychedelic microdosing. eLife. 10:e62878.
The protocol is for members.
Specific dosing, timing, and formulation guidance for each microdosing stack and outcome target lives in the member resource library. Free to join.
Request Membership